RedHill Biopharma Ltd (RDHL)

Oncology Corporate Profile

Stock Performance

12.7600
-0.0600

3 Month Stock History Chart

HQ Location

21 Ha'arba'a St.
Tel Aviv, Israel 64739

Company Description

RedHill Biopharma Ltd, is an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer.

Website: http://www.redhillbio.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
RP101Hsp127 inhibitorPancreatic cancerII
ABC294640sphingosine kinase inhibitorDiffuse large B-cell Lymphoma (DLBCL)I
ABC294640 (+ YELIVA®)sphingosine kinase inhibitorMultiple MyelomaI
mesupronurokinase-type plasminogen (uPA) inhibitorVarious cancer typesI

View additional information on product candidates here »

Source: http://www.redhillbio.com

Recent News Headlines

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/17/2017 12:19 pm

8/17/2017 12:19 pm

8/17/2017 12:19 pm

8/17/2017 12:19 am

8/17/2017 12:19 am

8/17/2017 12:19 am

8/10/2017 06:19 am

8/10/2017 06:19 am

8/10/2017 06:19 am

7/31/2017 06:27 am

7/31/2017 06:27 am

7/27/2017 06:19 am

7/27/2017 06:19 am

7/27/2017 12:19 am

7/25/2017 12:19 pm

7/17/2017 06:19 am

7/17/2017 06:19 am

7/12/2017 06:19 am

7/12/2017 12:19 am

6/19/2017 12:20 am

6/19/2017 12:20 am

6/13/2017 06:19 am